Groupama Asset Managment Grows Stock Position in Denali Therapeutics Inc. $DNLIMarket Beat·16 hours agoDNLI-5.46%BAC+0.36%
Denali Therapeutics sells priority review voucher for $195 million gross proceedsPUBT·Jul 28 at 05:04 AMDNLI-5.46%
Denali Therapeutics schedules quarterly results release and conference callPUBT·Jul 27 at 03:01 PMDNLI-5.46%
Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions ReturnSimplywall·Jul 19 at 04:15 PMDNLI-5.46%
Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)Tip Ranks·Jul 13 at 10:15 AMDNLI-5.46%RANK+1.65%
Denali wins FDA accelerated approval for Hunter syndrome brain-penetrant enzyme therapy AVLAYAHPUBT·Jul 9 at 03:05 PMDNLI-5.46%
Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher SaleSimplywall·Jun 23 at 10:13 PMDNLI-5.46%
Pfizer CFO to step down; Denali sells a regulatory fast-passbiopharmadive·Jun 22 at 05:04 AMGSK-0.73%PFE+0.40%
Denali Therapeutics to sell rare pediatric disease priority review voucher for $195 millionPUBT·Jun 18 at 07:05 AMDNLI-5.46%
Denali Therapeutics (DNLI) Stock Valuation After Setback In LUMA Trial And Focus On BEACON StudySimplywall·Jun 13 at 12:37 PMDNLI-5.46%
Does Denali Therapeutics (DNLI) Parkinson’s Setback Reveal a Deeper Shift in Its Neuroscience Strategy?Simplywall·Jun 1 at 12:27 PMBIIB-2.40%DNLI-5.46%
